146 related articles for article (PubMed ID: 12040453)
1. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
Rex JH; Anaissie EJ; Boutati E; Estey E; Kantarjian H
Leukemia; 2002 Jun; 16(6):1197-9. PubMed ID: 12040453
[No Abstract] [Full Text] [Related]
2. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M
Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study.
Egerer G; Geist MJ
Mycoses; 2011 Jan; 54 Suppl 1():7-11. PubMed ID: 21126266
[TBL] [Abstract][Full Text] [Related]
4. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.
Dellacasa CM; Busca A; Audisio E; Marmont F; Barbui AM; Falda M; De Rosa FG; Frairia C; Allione B; D'Ardia S; Aydin S; Pecoraro C; Manetta S; Vitolo U
J Chemother; 2014 Oct; 26(5):315-20. PubMed ID: 24075616
[No Abstract] [Full Text] [Related]
5. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
Selvy N; Villiet M; Hansel-Esteller S
Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
[TBL] [Abstract][Full Text] [Related]
6. Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S; Yildirim I; Ceyhan M; Cetin M; Tuncer M; Kara A; Cengiz AB; Seçmeer G; Yetgin S
Turk J Pediatr; 2010; 52(2):121-5. PubMed ID: 20560245
[TBL] [Abstract][Full Text] [Related]
7. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Lewis G; Hall P; Eisa N; Deremer D; Dobbins R; El-Geneidy M; Jillella A; Ustun C
Acta Haematol; 2010; 124(4):206-13. PubMed ID: 21071929
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials.
Ziakas PD; Kourbeti IS; Voulgarelis M; Mylonakis E
Clin Ther; 2010 Dec; 32(14):2316-36. PubMed ID: 21353103
[TBL] [Abstract][Full Text] [Related]
10. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Fisher BT; Zaoutis T; Dvorak CC; Nieder M; Zerr D; Wingard JR; Callahan C; Villaluna D; Chen L; Dang H; Esbenshade AJ; Alexander S; Wiley JM; Sung L
JAMA; 2019 Nov; 322(17):1673-1681. PubMed ID: 31688884
[TBL] [Abstract][Full Text] [Related]
11. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
12. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
13. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve.
Portugal RD; Garnica M; Nucci M
J Clin Oncol; 2009 Aug; 27(23):3849-54. PubMed ID: 19597026
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
15. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
16. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
17. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
[TBL] [Abstract][Full Text] [Related]
18. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias.
Khalafallah A; Maiwald M; Hannan T; Abell S; Staker J; Supperamohan A
Intern Med J; 2012 Feb; 42(2):131-6. PubMed ID: 22151972
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
AbuTarif MA; Krishna G; Statkevich P
Curr Med Res Opin; 2010 Feb; 26(2):397-405. PubMed ID: 20001450
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation.
Gupta S; Almyroudis NG; Battiwalla M; Bambach BJ; McCarthy PL; Proefrock AD; Ball D; Paplham P; Varma A; Kwon-Chung J; Segal BH
Transpl Infect Dis; 2007 Jun; 9(2):156-60. PubMed ID: 17462004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
